HUE057258T2 - Szerkesztett Botulinum neurotoxin - Google Patents
Szerkesztett Botulinum neurotoxinInfo
- Publication number
- HUE057258T2 HUE057258T2 HUE16714713A HUE16714713A HUE057258T2 HU E057258 T2 HUE057258 T2 HU E057258T2 HU E16714713 A HUE16714713 A HU E16714713A HU E16714713 A HUE16714713 A HU E16714713A HU E057258 T2 HUE057258 T2 HU E057258T2
- Authority
- HU
- Hungary
- Prior art keywords
- botulinum neurotoxin
- engineered botulinum
- engineered
- neurotoxin
- botulinum
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/952—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562138818P | 2015-03-26 | 2015-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE057258T2 true HUE057258T2 (hu) | 2022-05-28 |
Family
ID=55661643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16714713A HUE057258T2 (hu) | 2015-03-26 | 2016-03-25 | Szerkesztett Botulinum neurotoxin |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11268080B2 (hu) |
| EP (2) | EP3981783A1 (hu) |
| CN (2) | CN107548402B (hu) |
| DK (1) | DK3274364T3 (hu) |
| ES (1) | ES2895853T3 (hu) |
| HK (2) | HK1248737A1 (hu) |
| HU (1) | HUE057258T2 (hu) |
| PL (1) | PL3274364T3 (hu) |
| PT (1) | PT3274364T (hu) |
| RU (1) | RU2746736C2 (hu) |
| TW (1) | TWI725963B (hu) |
| WO (1) | WO2016154534A1 (hu) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102060355B1 (ko) | 2012-05-30 | 2019-12-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 가공된 보툴리눔 신경독소 |
| DK3274364T3 (da) * | 2015-03-26 | 2021-10-18 | Harvard College | Modificeret botulinumneurotoksin |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| PT3481852T (pt) * | 2016-07-08 | 2023-02-22 | Childrens Medical Center | Nova neurotoxina botulínica e seus derivados |
| EP3504226A1 (en) * | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| FI3529616T3 (fi) * | 2016-10-20 | 2023-12-04 | Harvard College | In vitro- ja solupohjaisia testejä botuliinineurotoksiinien aktiivisuuden mittaamiseksi |
| TWI810228B (zh) | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | 自主神經系統障礙之治療 |
| SE542539C2 (en) * | 2018-02-26 | 2020-06-02 | Toxotech Ab | Chimeric botulinum neurotoxin heavy chain binding domain |
| US20210148923A1 (en) * | 2018-05-30 | 2021-05-20 | The Governing Council Of The University Of Toronto | Methods and kits for identifying a protein associated with receptor-ligand interactions |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| GB202001353D0 (en) | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
| JP2023517724A (ja) | 2020-03-16 | 2023-04-26 | イプセン バイオファーム リミテッド | 四肢痙縮の処置のための改変されたボツリヌス神経毒素 |
| GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| CN114958887A (zh) * | 2021-02-26 | 2022-08-30 | 重庆誉颜制药有限公司 | 一种经修饰的毒素多肽的制备方法 |
| EP4313120A1 (en) | 2021-03-30 | 2024-02-07 | Ipsen Biopharm Limited | Treatment of pain & inflammatory disorders |
| BR112023018473A2 (pt) | 2021-03-30 | 2023-11-14 | Ipsen Biopharm Ltd | Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios |
| CA3231083A1 (en) | 2021-09-16 | 2023-03-23 | Nicolae GRIGORE | Modified bont/a for use in the treatment of cervical dystonia |
| GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
| WO2023047127A1 (en) | 2021-09-23 | 2023-03-30 | Ipsen Biopharm Limited | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| CA3234608A1 (en) | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
| GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
| US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| PT1086702E (pt) | 1994-05-09 | 2005-08-31 | William J Binder | Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca |
| DE69511860T2 (de) | 1994-05-31 | 2000-02-10 | Allergan Inc | Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine |
| GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| WO1998008540A1 (en) | 1996-08-28 | 1998-03-05 | Ophidian Pharmaceuticals, Inc. | Multivalent vaccine for clostridium botulinum neurotoxin |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| EP1531859A4 (en) * | 2002-05-31 | 2005-12-07 | Univ Jefferson | COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT |
| US7148041B2 (en) | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
| JP4970057B2 (ja) | 2004-02-24 | 2012-07-04 | アラーガン、インコーポレイテッド | ボツリヌス毒素スクリーニングアッセイ |
| KR100668570B1 (ko) | 2004-06-28 | 2007-01-16 | 입센 리미티드 | 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물 |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| AU2006225116B2 (en) | 2005-03-15 | 2012-04-19 | Allergan, Inc. | Modified Clostridial toxins with altered targeting capabilities for Clostridial toxin target cells |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| US7985554B2 (en) | 2005-10-14 | 2011-07-26 | Wisconsin Alumni Research Foundation | Botulinum neurotoxin A receptor and the use thereof |
| DE102005051789B4 (de) | 2005-10-28 | 2014-08-07 | Toxogen Gmbh | Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen |
| FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
| FR2907680B1 (fr) * | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
| FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
| WO2009015840A2 (en) * | 2007-07-27 | 2009-02-05 | Merz Pharma Gmbh & Co. Kgaa | Polypeptide for targeting of neural cells |
| US8586081B2 (en) | 2007-09-20 | 2013-11-19 | University Of Massachusetts | Detoxified recombinant botulinum neurotoxin |
| WO2009042165A2 (en) * | 2007-09-25 | 2009-04-02 | Thomas Jefferson University | Mutant botulinum neurotoxin serotype a polypeptide and uses thereof |
| FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
| AU2009286973B2 (en) | 2008-08-29 | 2014-06-12 | Merz Pharma Gmbh & Co. Kgaa | Clostridial neurotoxins with altered persistency |
| US20100196445A1 (en) | 2008-11-12 | 2010-08-05 | David Nathaniel E | Systems and methods for delivery of biologically active agents |
| EP2419128B1 (en) | 2009-04-14 | 2018-06-06 | Medical College of Wisconsin, Inc. | Engineered botulinum neurotoxin |
| US8440204B2 (en) | 2009-04-30 | 2013-05-14 | Wisconsin Alumni Research Foundation | Subtype of Closteridium botulinum neurotoxin type A and uses thereof |
| MX369263B (es) | 2010-05-20 | 2019-11-04 | Allergan Inc | Toxinas de clostridium degradables. |
| KR102060355B1 (ko) * | 2012-05-30 | 2019-12-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 가공된 보툴리눔 신경독소 |
| GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| US9216210B2 (en) * | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| DK3274364T3 (da) * | 2015-03-26 | 2021-10-18 | Harvard College | Modificeret botulinumneurotoksin |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| AU2017277905B2 (en) * | 2016-06-08 | 2022-04-14 | Children's Medical Center Corporation | Engineered Botulinum neurotoxins |
| EP3504226A1 (en) | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
-
2016
- 2016-03-25 DK DK16714713.1T patent/DK3274364T3/da active
- 2016-03-25 TW TW105109524A patent/TWI725963B/zh active
- 2016-03-25 US US15/561,355 patent/US11268080B2/en active Active
- 2016-03-25 CN CN201680025744.6A patent/CN107548402B/zh active Active
- 2016-03-25 ES ES16714713T patent/ES2895853T3/es active Active
- 2016-03-25 RU RU2017134357A patent/RU2746736C2/ru active
- 2016-03-25 HU HUE16714713A patent/HUE057258T2/hu unknown
- 2016-03-25 PL PL16714713T patent/PL3274364T3/pl unknown
- 2016-03-25 CN CN202210985546.1A patent/CN115925835A/zh active Pending
- 2016-03-25 WO PCT/US2016/024211 patent/WO2016154534A1/en active Application Filing
- 2016-03-25 PT PT167147131T patent/PT3274364T/pt unknown
- 2016-03-25 EP EP21189503.2A patent/EP3981783A1/en active Pending
- 2016-03-25 EP EP16714713.1A patent/EP3274364B1/en active Active
-
2018
- 2018-07-04 HK HK18108651.3A patent/HK1248737A1/zh unknown
- 2018-07-06 HK HK18108739.9A patent/HK1249119A1/zh unknown
-
2022
- 2022-01-24 US US17/582,958 patent/US20220154160A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016154534A1 (en) | 2016-09-29 |
| US20180080016A1 (en) | 2018-03-22 |
| CN115925835A (zh) | 2023-04-07 |
| EP3274364B1 (en) | 2021-08-04 |
| ES2895853T3 (es) | 2022-02-22 |
| HK1248737A1 (zh) | 2018-10-19 |
| US11268080B2 (en) | 2022-03-08 |
| CN107548402A (zh) | 2018-01-05 |
| RU2746736C2 (ru) | 2021-04-20 |
| US20220154160A1 (en) | 2022-05-19 |
| DK3274364T3 (da) | 2021-10-18 |
| TW201639877A (zh) | 2016-11-16 |
| PT3274364T (pt) | 2021-11-05 |
| EP3981783A1 (en) | 2022-04-13 |
| HK1249119A1 (zh) | 2018-10-26 |
| CN107548402B (zh) | 2022-08-19 |
| RU2017134357A (ru) | 2019-04-05 |
| PL3274364T3 (pl) | 2022-01-10 |
| RU2017134357A3 (hu) | 2020-03-25 |
| EP3274364A1 (en) | 2018-01-31 |
| TWI725963B (zh) | 2021-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249119A1 (zh) | 工程改造的肉毒桿菌神經毒素 | |
| IL263058A (en) | Engineered botulinum neurotoxins | |
| HK1257676A1 (zh) | 工程化 crispr-cas 9 核酸酶 | |
| ZA201900341B (en) | A novel botulinum neurotoxin and its derivatives | |
| HK1245292A1 (zh) | 陽離子神經毒素 | |
| HK1210692A1 (en) | Engineered botulinum neurotoxin | |
| SG11201607400VA (en) | Manufacture of recombinant clostridium botulinum neurotoxins | |
| IL253429B (en) | A container filled with botulinum toxin | |
| GB201621111D0 (en) | Neurotoxins | |
| IL259185B (en) | Thrombin microcapsules | |
| DK3347540T3 (en) | Bærer til et lineært loftspanel | |
| HK1249147A1 (zh) | 用於增强細胞對肉毒神經毒素的特異性攝取的方法 | |
| IL287719A (en) | Stabilized thrombin | |
| GB201600979D0 (en) | Jft |